Pro-PBD TAM killer

Endocyte’s new ProPBD SMDC employs a highly potent DNA-reactive drug to attack cancer from two directions, by targeting not just the cancer cells, but also the cells that have been recruited by the tumor to support its growth. These supportive cells are known as tumor-associated macrophages, or TAMs, and they allow tumors to form new blood vessels, avoid immune detection, metastasize, and grow. The high expression of the folate receptor on cancer cells and TAMs provides a targeted therapeutic advantage, and a novel opportunity for a single SMDC to treat cancer with a powerful dual mechanism of action.

Other videos...